Navigation Links
CuraGen Reports Third Quarter 2008 Financial Results
Date:11/3/2008

September 30, September 30,

2008 2007 2008 2007

(unaudited) (unaudited)

Collaboration revenue $- $22 $1,174 $66

Operating expenses:

Research and development 3,453 8,074 12,459 30,480

General and administrative 1,076 2,568 4,235 9,631

Restructuring and other charges - 1,058 - 8,537

Total operating expenses 4,529 11,700 16,694 48,648

Gain on sale of intangible asset - - 36,397 -

(Loss) income from operations (4,529) (11,678) 20,877 (48,582)

Interest income 741 1,861 2,471 4,060

Interest expense (226) (1,273) (1,474) (4,172)

Gain on extinguishment of debt - 169 6,991 169

Gain on sale of long-term marketable

securities - 973 - 973

(Loss) income from continuing

operations before income taxes (4,014) (9,948) 28,865 (47,552)

Income tax benefit (provision) 32 50 (362) 160

(Loss) income from continuing

operations (3,982) (9,898) 28,503 (47,392)

Discontinued operations:

Loss from discontinued operations - - - (2,991)

Gain on sale of subsidiary - - - 78,352

Income from discontinued operations - - - 75,361

Net (loss) income ($3,982) ($9,898) $28,503 $27,969

Basic (loss) income per share from

continuing operations ($0.07) ($0.18) $0.50 ($0.85)

Basic income per share from

discontinued
'/>"/>

SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. CuraGen Repurchases $50.9 Million of 2011 Convertible Debt for $43.2 Million
2. CuraGen Sells Ownership of Belinostat to TopoTarget A/S
3. CuraGen to Present at the BIO CEO & Investor Conference
4. CuraGen Reports Fourth Quarter and Year End 2007 Financial Results
5. CuraGen Corporation Receives Notification from NASDAQ
6. CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
7. CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
8. CuraGen to Present at the 19th Annual Piper Jaffray Health Care Conference
9. CuraGen Appoints Clinical Oncologist as VP of Medical Development
10. CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer
11. BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015   GenoSpace , a leading provider ... analysis of genomic and other biomedical data, today ... the company as Vice President of Sales and ... "GenoSpace partners with its customers ... and explore complex sets of genomic, phenotypic and ...
(Date:7/30/2015)... CA (PRWEB) , ... July 30, 2015 , ... ... successful completion of a field clinical study of its canine osteoarthritis stem cell ... with Aratana Therapeutics (Kansas City, KS) and will be marketed in the US ...
(Date:7/30/2015)... 30, 2015 Ascendis Pharma A/S (Nasdaq: ... its innovative TransCon technology to address significant unmet ... a six-month Phase 2 study to evaluate the ... in 53 treatment-naïve, pre-pubertal children with growth hormone ... pleased with the top-line results from our Phase ...
(Date:7/30/2015)... ... July 30, 2015 , ... GEA's ... designed for continuous operation up to 1500 bar. The sanitary design gauge of ... preventing toxic contamination. , The Pony™ NS2006L homogenizer is an ideal solution for ...
Breaking Biology Technology:GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2
... ... Countries, - Competitors Precluded from Immediate Commercialization of Competitive ... Products, ... TSX.V.NTB) announces that the,European Patent Office (EPO) granted on May 31st 2007 Neptune,s composition,of ...
... Expected to Yield Multiple New Drug Products for Aida,s ... ... Calif., March 27 Aida,Pharmaceuticals, Inc (OTC Bulletin Board: AIDA) today ... Jiangsu,Institute of Microbiology Co., Ltd. ("JSIM") Aida,s subsidiary, Hanzhou,Aida Pharmaceuticals Co., ...
... through conversion of agricultural ... products into advanced materials, COLUMBUS, Ohio, ... representing a wide range of expertise in the,fields of chemicals, ... Chemicals, Polymers, and Advanced Materials Task Force. The,creation of the ...
Cached Biology Technology:Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications 2Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications 3Aida Acquires High-Level Research Institute in China 2Ohio Task Force Begins Mission of Creating a New 21st Century Industry 2Ohio Task Force Begins Mission of Creating a New 21st Century Industry 3
(Date:7/9/2015)... Calif. , July 9, 2015  Unchained ... today announcing its acquisition of Avid Nano. Avid ... light scattering (DLS) systems.    Also ... smallest, fastest and easiest to use protein sizing ... that measures a protein,s hydrodynamic size, size distribution, ...
(Date:7/8/2015)... , July 8, 2015 Summary Pancreatic ... the fourth most fatal, with a mortality rate of ... prognosis of pancreatic cancer patients has highlighted a significant ... is not being met by the current market. ... of products with varying molecule types and mechanisms of ...
(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... 7, 2008 The Global Innovation Imperatives (Gii) ... for their first session at the American Chemical ... Gii, a joint collaboration between the ACS Committee ... Industry, seeks to combat worldwide health, environmental and ...
... is a poorly understood condition that incapacitates and affects the ... In the US, it affects approximately six million women and ... It is a chronic painful disease which occurs when ... the area of the ovaries and fallopian tubes, but can ...
... the fact that millions of Americans are believed to have ... to treat many of these people. That is due in ... are varied and complex, ranging from chronic allergies, viral infection, ... percent of Americans have lost their sense of smell and ...
Cached Biology News:At ACS' national meeting, global initiative set to tackle water issues 2New study finds uncontrollable stress worsens symptoms of endometriosis 2New study finds uncontrollable stress worsens symptoms of endometriosis 3For some who have lost their sense of smell, a once popular asthma drug could help 2For some who have lost their sense of smell, a once popular asthma drug could help 3
Hamster serum...
... Dye Pack, 12 x Cy5. The ... for microarray labeling.Higher reactivity Cy3 and ... per vial, at > 75% reactive ... and packed in foil packs for ...
Collected from sexually mature, mixed sex, mixed breed dogs. Serum from specific breeds available by request....
... Power Supply, 1. 300 V, 400 ... constant current modes.Single-unit increments in settings ... for submarine, mini vertical, and standard ... semidry and mini tank blotting applications. ...
Biology Products: